1. Home
  2. SMBC vs ESPR Comparison

SMBC vs ESPR Comparison

Compare SMBC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Missouri Bancorp Inc.

SMBC

Southern Missouri Bancorp Inc.

HOLD

Current Price

$62.44

Market Cap

698.0M

Sector

Finance

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.75

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMBC
ESPR
Founded
1887
2008
Country
United States
United States
Employees
N/A
294
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
698.0M
731.9M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
SMBC
ESPR
Price
$62.44
$2.75
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$67.75
$7.60
AVG Volume (30 Days)
43.5K
4.8M
Earning Date
04-21-2026
03-10-2026
Dividend Yield
1.58%
N/A
EPS Growth
17.19
60.71
EPS
3.00
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$16.09
$2.92
Revenue Next Year
$5.69
N/A
P/E Ratio
$21.05
N/A
Revenue Growth
N/A
21.31
52 Week Low
$45.10
$0.73
52 Week High
$66.56
$4.18

Technical Indicators

Market Signals
Indicator
SMBC
ESPR
Relative Strength Index (RSI) 49.53 45.18
Support Level $59.32 $2.66
Resistance Level $63.54 $3.02
Average True Range (ATR) 1.62 0.18
MACD 0.13 0.04
Stochastic Oscillator 55.38 63.00

Price Performance

Historical Comparison
SMBC
ESPR

About SMBC Southern Missouri Bancorp Inc.

Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: